S. Arai

P. Lavori, S. Horning, D. Miklos, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity.

D. Miklos, R. Negrin, L. Muffly, 2017, Blood advances.

Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence.

B. Narasimhan, J. Zehnder, D. Miklos, 2012, Blood.

TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors.

Brit B. Turnbull, H. Kohrt, P. Lavori, 2009, Blood.

Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma

D. Miklos, A. Mcmillan, R. Negrin, 2012, Bone Marrow Transplantation.

A systematic approach to hepatic complications in hematopoietic stem cell transplantation.

Linda A. Lee, G. Vogelsang, S. Arai, 2002, Journal of hematotherapy & stem cell research.

Infusion of donor-derived CD8+ memory T cells for relapse following allogeneic hematopoietic cell transplantation.

D. Miklos, R. Negrin, L. Muffly, 2018, Blood advances.

Association of Foxp3 regulatory gene expression with graft-versus-host disease.

C. Thoburn, Richard J. Jones, E. Matsui, 2004, Blood.

Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma

D. Iberri, D. Miklos, M. Liedtke, 2020, Bone Marrow Transplantation.

Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents.

D. Miklos, R. Negrin, L. Muffly, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Regulation of OX40 gene expression in graft-versus-host disease.

C. Thoburn, A. Hess, S. Arai, 2005, Transplantation proceedings.

Identification of Bruton's tyrosine kinase (Btk) gene mutations and characterization of the derived proteins in 35 X-linked agammaglobulinemia families: a nationwide study of Btk deficiency in Japan.

T. Kunikata, T. Yamadori, T. Miyawaki, 1996, Blood.

Design and Patient Characteristics of the Chronic Graft-versus-Host Disease Response Measures Validation Study.

J. Pidala, Stephanie J. Lee, M. Flowers, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease.

D. Miklos, B. Storer, Jingxin Qiu, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease.

B. Storer, J. Pidala, Stephanie J. Lee, 2017, Blood.

Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease.

W. Wood, B. Kurland, J. Pidala, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A Changing Landscape of Mortality for Systemic Light Chain Amyloidosis.

S. Schrier, M. Liedtke, R. Lafayette, 2019, JACC. Heart failure.

Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis.

S. Schrier, M. Liedtke, R. Lafayette, 2014, Heart rhythm.

Identification and characterization of a novel SH3-domain binding protein, Sab, which preferentially associates with Bruton's tyrosine kinase (BtK).

T. Kunikata, T. Yamadori, Y. Baba, 1998, Biochemical and biophysical research communications.

Outcomes After Heart Transplantation for Amyloid Cardiomyopathy in the Modern Era

M. Wheeler, S. Schrier, M. Liedtke, 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Heart transplantation and cardiac amyloidosis: approach to screening and novel management strategies.

S. Schrier, M. Liedtke, R. Lafayette, 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Epidemiology of lower respiratory tract infections and community-acquired respiratory viruses in patients with bronchiolitis obliterans syndrome after hematopoietic cell transplant: a retrospective cohort study.

V. Sundaram, J. Hsu, H. Sharifi, 2022, Transplantation and cellular therapy.

Outcomes in Patients With Cardiac Amyloidosis Undergoing Heart Transplantation.

M. Wheeler, S. Schrier, M. Liedtke, 2020, JACC. Heart failure.

Rituximab in hematopoietic cell transplantation

D. Miklos, S. Arai, 2010, Expert opinion on biological therapy.

Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma.

D. Miklos, R. Hoppe, R. Negrin, 2020, Blood advances.

Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY

D. Miklos, R. Negrin, S. Arai, 2011, Bone Marrow Transplantation.

Clinicopathologic Threshold of Acute Colorectal Graft-versus-Host Disease.

N. Kambham, Adam J Gomez, S. Arai, 2016, Archives of pathology & laboratory medicine.

Crypt loss is a marker of clinical severity of acute gastrointestinal graft‐versus‐host disease

A. Keshavarzian, S. Jakate, J. Melson, 2007, American journal of hematology.

Hepatitic variant of graft-versus-host disease after donor lymphocyte infusion.

M. Torbenson, J. Boitnott, Linda A. Lee, 2002, Blood.

Allogeneic hematopoietic cell transplant for normal karyotype acute myeloid leukemia: Indirect evidence of selection for adverse molecular profile

D. Miklos, R. Negrin, S. Arai, 2015, Bone Marrow Transplantation.

European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation

L. Tian, D. Miklos, R. Negrin, 2014, Blood Cancer Journal.

Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era.

D. Miklos, K. Cunanan, L. Muffly, 2022, Transplantation and cellular therapy.

Chronic Graft versus Host Disease: Interdisciplinary Management: Incidence and Trends

M. Arora, S. Arai, D. Rizzo, 2009 .

Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors.

W. Wood, B. Storer, J. Pidala, 2016, Blood.

Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis.

S. Schrier, M. Liedtke, R. Lafayette, 2017, Blood.

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study

A. Logan, D. Howard, J. Liesveld, 2021, Blood.

Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease

P. Richardson, S. Mineishi, D. Niederwieser, 2012, Therapeutic advances in hematology.

Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome.

Allen R. Chen, Zhezhen Jin, P. Richardson, 2002, Blood.

Myxedema ascites in the posttransplant setting: Case report

Linda A. Lee, G. Vogelsang, S. Arai, 2002, American journal of hematology.

State-of-the-Art Review A Systematic Approach to Hepatic Complications in Hematopoietic Stem Cell Transplantation

Linda A. Lee, G. Vogelsang, S. Arai, 2002 .

Grading cardiac response in AL amyloidosis: implications for relapse and survival

S. Schrier, M. Liedtke, R. Lafayette, 2019, British journal of haematology.

Complete donor T‐cell engraftment 30 days after allogeneic transplantation predicts molecular remission in high‐risk chronic lymphocytic leukaemia

J. Zehnder, D. Miklos, D. Tyan, 2010, British journal of haematology.

Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease

J. Pidala, Stephanie J. Lee, M. Flowers, 2015, Haematologica.

Comorbidity Burden in Patients with Chronic Graft Versus Host Disease

W. Wood, B. Storer, J. Pidala, 2014 .

Hematopoietic stem cell transplantation: bone marrow vs. mobilized peripheral blood.

H. Klingemann, S. Arai, 2003, Archives of medical research.

Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients.

D. Miklos, B. Sahaf, Sai-Wen Tang, 2019, JCI insight.

H–Y antigen-binding B cells develop in male recipients of female hematopoietic cells and associate with chronic graft vs. host disease

D. Miklos, L. Herzenberg, B. Sahaf, 2013, Proceedings of the National Academy of Sciences.

Final results from a defibrotide treatment‐IND study for patients with hepatic veno‐occlusive disease/sinusoidal obstruction syndrome

P. Richardson, S. Grupp, R. Soiffer, 2018, British journal of haematology.

Management of graft-versus-host disease.

G. Vogelsang, S. Arai, G. Vogelsang, 2000, Blood reviews.

Belumosudil for Chronic Graft-Versus-Host Disease (cGVHD) after 2 or More Prior Lines of Therapy: The Rockstar Study (KD025-213)

Stephanie J. Lee, O. Schueller, B. Blazar, 2020, Transplantation and Cellular Therapy.

Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial.

E. Leifer, H. Deeg, P. Westervelt, 2022, The Lancet. Haematology.

Donor-derived MDS/AML in families with germline GATA2 mutation.

J. Klco, S. Holland, N. Young, 2018, Blood.

Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias.

A. J. Goodell, J. Zehnder, M. Liedtke, 2022, Seminars in oncology.

Short tandem repeat and human leukocyte antigen mutations or losses confound engraftment and typing analysis in hematopoietic stem cell transplants.

A. Cherry, F. Grumet, S. Pereira, 2011, Human immunology.

Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation.

D. Miklos, R. Negrin, R. Armstrong, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Role of Immunotherapy in Stem Cell Transplantation

H. Klingemann, S. Arai, 2003, International journal of hematology.

Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduce

N. Geller, P. Hari, D. Porter, 2019, The Lancet. Haematology.

Comorbidity burden in patients with chronic GVHD

W. Wood, B. Storer, J. Pidala, 2013, Bone Marrow Transplantation.

Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium.

B. Kurland, J. Pidala, Stephanie J. Lee, 2011, Blood.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.

Daniel Wolff, Yoshihiro Inamoto, Sandra A Mitchell, 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation

W. Wood, D. Miklos, B. Storer, 2015, Clinical Cancer Research.

Successful surgical and medical treatment of rhizopus osteomyelitis following hematopoietic cell transplantation.

N. Vashi, J. Brown, S. Arai, 2012, Orthopedics.

More than a frog in the throat: a case series and review of localized laryngeal amyloidosis.

RyanA . Stevenson, S. Schrier, M. Liedtke, 2012, Archives of otolaryngology--head & neck surgery.

Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma.

D. Miklos, B. Sahaf, C. Mackall, 2021, Blood advances.

Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms.

H. Kohrt, P. Lavori, D. Miklos, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Post–hematopoietic stem cell transplantation immune-mediated anemia: a literature review and novel therapeutics

R. Childs, S. Arai, Y. Migdady, 2021, Blood advances.

A fructo-oligosaccharide prebiotic is well-tolerated in adults undergoing allogeneic hematopoietic stem cell transplantation: a phase I dose-escalation trial

H. Hedlin, A. Fodor, D. Miklos, 2021, medRxiv.

Involvement of wiskott-aldrich syndrome protein in B-cell cytoplasmic tyrosine kinase pathway.

H. Ochs, T. Kunikata, T. Yamadori, 1999, Blood.

A novel BTB/POZ transcriptional repressor protein interacts with the Fanconi anemia group C protein and PLZF.

A Zelent, J. Licht, A. Melnick, 1999, Blood.

Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant

S. Horning, T. Illidge, A. Younes, 2013, Leukemia & lymphoma.

Transcriptional Functions Residues Required for Biological and BTB / POZ Domain Reveals Motifs and Promyelocytic Leukemia Zinc Finger In-Depth Mutational Analysis of the

J. Licht, A. Melnick, K. Borden, 2000 .

Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research.

Tao Wang, Thomas Spitzer, Daniel J Weisdorf, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Assessment of Joint and Fascia Manifestations in Chronic Graft‐Versus‐Host Disease

J. Goldberg, B. Kurland, J. Pidala, 2014, Arthritis & rheumatology.

Minimal Residual Disease Monitoring with High-Throughput Sequencing of T Cell Receptors in Cutaneous T Cell Lymphoma

C. Desmarais, R. Hoppe, Youn H. Kim, 2013, Science Translational Medicine.

Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.

W. Wood, J. Pidala, Stephanie J. Lee, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels.

E. Leifer, H. Deeg, J. Tolar, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.

D. Miklos, R. Negrin, L. Muffly, 2021, Transplantation and cellular therapy.

Successful treatment of thrombocytopenia with daratumumab after allogeneic transplant: a case report and literature review.

S. Arai, F. Socola, Y. Migdady, 2020, Blood advances.

Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment.

M. Zahurak, G. Vogelsang, S. Arai, 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study.

E. Leifer, H. Deeg, M. Horowitz, 2015, The Lancet. Haematology.

Association of Socioeconomic Status with Chronic Graft-versus-Host Disease Outcomes.

J. Pidala, L. Rybicki, Stephanie J. Lee, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Measurement of oral chronic GVHD: results from the Chronic GVHD Consortium

B. Kurland, J. Pidala, M. Flowers, 2013, Bone Marrow Transplantation.

Real-World Experience of Cryopreserved Allogeneic Hematopoietic Grafts during the COVID-19 Pandemic: A Single-Center Report

D. Miklos, R. Negrin, L. Muffly, 2022, Transplantation and Cellular Therapy.

Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings

G. Vogelsang, S. Arai, G. Vogelsang, 2001, Bone Marrow Transplantation.

A Case Report of Refractory Immune Thrombocytopenia (ITP) Following Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplantation (HCT) for Myelodysplastic Syndrome (MDS) Successfully Treated with Off-Label Use of Daratumumab

S. Arai, F. Socola, Y. Migdady, 2018, Blood.

A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies

D. Miklos, Jingxin Qiu, M. Flowers, 2011 .

Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802.

W. Wood, J. Pidala, E. Holler, 2018, Blood advances.

Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease

B. Storer, J. Pidala, Stephanie J. Lee, 2014, Haematologica.

Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study

B. Storer, J. Pidala, Stephanie J. Lee, 2012, Haematologica.

Prophylactic Rituximab after Reduced Intensity Conditioning Transplantation Results in Low Chronic Gvhd

P. Lavori, D. Miklos, B. Sahaf, 2008 .

Prevention of graft versus host disease with Hematopoietic CellTransplantation with Reduced Intensity Conditioning—a comparison of threeprophylaxis regimens (tacrolimus/mycophenolate mofetil/cyclophosphamide,tacrolimus/methotrexate/bortezomib or tacrolimus/methotrexate/maraviroc) versustacrolimus/me

N. Geller, P. Hari, M. Pasquini, 2019 .

Rituximab Provides Steroid-Sparing Therapy in New-Onset Chronic Graft-Versus-Host Disease

A. Logan, D. Miklos, B. Sahaf, 2013 .

Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium

J. Pidala, Z. DeFilipp, Stephanie J. Lee, 2021, Blood advances.

Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma

Matthew J. Frigault, R. Houot, V. Torri, 2021, Leukemia.

Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy

J. Zehnder, D. Miklos, C. Mackall, 2021, Blood advances.

Natural Killer Cells for Adoptive Immunotherapy

S. Arai, J. Benjamin, 2010 .

Impaired B Cell Clonotype Diversification After Allogeneic Hematopoietic Cell Transplantation Predicts Graft-Versus-Host Disease

V. Carlton, A. Logan, M. Faham, 2013 .

Initial therapy for chronic graft-versus-host disease: analysis of practice variation and failure-free survival

J. Pidala, Stephanie J. Lee, M. Arora, 2021, Blood advances.

Early CMV viremia is associated with impaired viral control following nonmyeloablative hematopoietic cell transplantation with a total lymphoid irradiation and antithymocyte globulin preparative regimen.

C. Rhee, D. Ho, J. Schaenman, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation

K. Ness, M. Flowers, M. Arora, 2009, Bone Marrow Transplantation.

Durable discontinuation of systemic therapy in patients affected by chronic graft-versus-host disease

J. Pidala, Stephanie J. Lee, M. Arora, 2022, Haematologica.

Potential Association of Anti-CCR4 Antibody Mogamulizumab and Graft-vs-Host Disease in Patients With Mycosis Fungoides and Sézary Syndrome

M. Khodadoust, Youn H. Kim, S. Arai, 2018, JAMA dermatology.

Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement

S. Schrier, M. Liedtke, R. Lafayette, 2013, Haematologica.

Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation.

V. Sundaram, D. Miklos, Lingyao Yang, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Sirolimus and Mycophenolate Mofetil as Graft-versus-Host Disease Prophylaxis in Myeloablative, Matched Related Donor Hematopoietic Cell Transplantation

P. Lavori, D. Miklos, M. Florek, 2008, Bone Marrow Transplantation.

Trends In Incidence, Presentation, and Outcomes Of Chronic Graft-Versus-Host Disease In Allogeneic Transplantation- Report From The Center For International Blood and Marrow Transplant Research

S. Spellman, Tao Wang, M. Arora, 2013 .

Rituximab Infusion Two Months after HCT Decreases Alloreactive B Cell Responses While Recipient Plasma Cells Persist.

Julie R. Boiko, D. Miklos, B. Sahaf, 2008 .

Rituximab Infusion Two Months after Nonmyeloablative Transplantation Maintains B-Cell Disease Control with Minimal GVHD.

J. Zehnder, D. Miklos, B. Sahaf, 2006 .

Long-awaited news for hepatic veno-occlusive disease.

S. Arai, 2016, Blood.

Updated Results from the Ongoing US Treatment IND Study Using Defibrotide for Patients with Hepatic Veno-Occlusive Disease

P. Richardson, S. Grupp, R. Soiffer, 2015 .

Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor vs. G-CSF +/- Plerixafor in the Lenalidomide Era.

D. Miklos, R. Negrin, L. Muffly, 2021, Transplantation and cellular therapy.

Amphiregulin Improves Stratification of the Refined Minnesota Acute Graft-Versus-Host Disease Risk Score: Results from BMT CTN 0302/0802

W. Wood, J. Pidala, E. Holler, 2017 .

Clinical Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) Using Nonmyeloablative Host Conditioning with Total Lymphoid Irradiation and Anti-Thymocyte Globulin Confirm a Low Incidence of Graft Versus Host Disease (GVHD) and Retained Graft Anti-Tumor Activity.

D. Miklos, R. Negrin, S. Strober, 2006 .

Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma

D. Iberri, D. Miklos, M. Liedtke, 2021, Bone Marrow Transplantation.

Herpes simplex virus hepatitis: expanding the spectrum of disease

A. N. Duckro, M. Hayden, S. Arai, 2006, Transplant infectious disease : an official journal of the Transplantation Society.

Interaction between plzf and eto-a possible link in the molecular mechanisms of M2 and M3 leukemia

J. Licht, A. Melnick, J. Westendorf, 2000 .

Checkpoint inhibitor‐based salvage regimens prior to autologous stem cell transplant improve event‐free survival in relapsed/refractory classic Hodgkin lymphoma

R. Advani, S. Ansell, K. Dorritie, 2023, American journal of hematology.

A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer.

A. Kurian, A. Garber, S. Arai, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

B. Kurland, M. Flowers, M. Arora, 2012 .

Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia.

V. Sundaram, D. Miklos, M. Liedtke, 2021, Blood advances.

391: Rituximab Infusion after Allogeneic HCT Prevents Donor B Cell Reconstitution and Alloimmunity One Year Post Transplant

Julie R. Boiko, D. Miklos, B. Sahaf, 2008 .

283: Rituximab infusion two months after total lymphoid irradiation-antithymocyte globulin (TLI-ATG) nonmyeloablative transplantation maintains B-cell disease control with minimal GVHD

J. Zehnder, D. Miklos, B. Sahaf, 2007 .

Monitoring Measurable Residual Disease Using Peripheral Blood in Acute Lymphoblastic Leukemia: Results of a Prospective, Observational Study

V. Sundaram, D. Miklos, M. Liedtke, 2020 .

Orca-T Results in High Gvhd-Free and Relapse-Free Survival Following Myeloablative Conditioning for Hematological Malignancies: Results of a Single Center Phase 2 and a Multicenter Phase 1b Study

D. Miklos, B. Shaw, R. Negrin, 2021, Blood.

A phase I trial with extended cohort of gemcitabine and vinorelbine followed by autologous peripheral blood stem cell transplantation for recurrent or refractory Hodgkin’s lymphoma

S. Horning, R. Negrin, S. Arai, 2005 .

Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms

L. Tian, D. Miklos, R. Negrin, 2015 .

Defibrotide (DF) in the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) Following Stem Cell Transplantation (SCT): Results of a Phase 3 Study Utilizing a Historical Control.

R. D'Agostino, J. Massaro, P. Richardson, 2009 .

Organ responses with daratumumab therapy in previously treated AL amyloidosis.

S. Schrier, M. Liedtke, R. Lafayette, 2020, Blood advances.

Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents.

R. Advani, D. Miklos, R. Hoppe, 2023, Blood.

Non-Myeloablative Allogeneic Transplantation Resulting in Clinical and Molecular Remission with Low Non-Relapse Mortality (NRM) in Patients with Advanced Stage Mycosis Fungoides (MF) and Sézary Syndrome (SS)

D. Miklos, R. Hoppe, R. Negrin, 2014 .

Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia

J. Zehnder, A. Cherry, D. Arber, 2016, Leukemia.

Haploidentical Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) Conditioning Protects Against Acute Graft Versus Host Disease (GVHD).

D. Miklos, B. Sahaf, R. Negrin, 2005 .

CD22-CAR T-Cell Therapy Mediates High Durable Remission Rates in Adults with Large B-Cell Lymphoma Who Have Relapsed after CD19-CAR T-Cell Therapy

K. Davis, Y. Natkunam, D. Miklos, 2021, Blood.

Minimal Residual Disease Monitoring with High-Throughput Sequencing of T Cell Receptors in Cutaneous T Cell Lymphoma

C. Desmarais, R. Hoppe, Youn H. Kim, 2013, Science Translational Medicine.

Outcomes After Heart Transplantation for Amyloid Cardiomyopathy in the Modern Era

M. Wheeler, S. Schrier, M. Liedtke, 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria.

B. Storer, J. Pidala, Stephanie J. Lee, 2011, Blood.

An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease.

B. Storer, J. Pidala, Stephanie J. Lee, 2017, Blood.

Patient-reported treatment response in chronic graft-versus-host disease

J. Pidala, A. Im, M. Flowers, 2023, Haematologica.

A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies.

D. Miklos, Jingxin Qiu, M. Flowers, 2011, Blood.

Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients.

D. Miklos, B. Sahaf, Sai-Wen Tang, 2019, JCI insight.

Defibrotide (DF) in the Treatment of Hepatic Veno-Occlusive Disease (VOD) in Stem Cell Transplant (SCT) and Non-SCT Patients (Pts): Early Intervention Improves Outcome - Updated Results of a Treatment IND Expanded Access Protocol

R. D'Agostino, J. Massaro, P. Richardson, 2011 .